Furthermore, PCV requires a repeated treatment schedule causing frequent visits to the hospital, which may pose significant emotional and financial burden to the affected individuals as is reported in patients with n-AMD undergoing anti-VEGF treatment [9,10]. The gene discussed is VEGFA; the disease is age-related macular degeneration.